Changes to the Australian Pharmaceutical Benefit Scheme restrictions for biological disease-modifying antirheumatic drugs have influenced the use of leflunomide

Ashley M. Hopkins, Agnès Isabelle Vitry, Catherine E. O'Doherty, Susanna M. Proudman, Michael D. Wiese

Research output: Contribution to journalLetterpeer-review

1 Citation (Scopus)

Fingerprint

Dive into the research topics of 'Changes to the Australian Pharmaceutical Benefit Scheme restrictions for biological disease-modifying antirheumatic drugs have influenced the use of leflunomide'. Together they form a unique fingerprint.

Medicine & Life Sciences